{"id":23353,"date":"2025-10-23T18:00:10","date_gmt":"2025-10-23T17:00:10","guid":{"rendered":"https:\/\/jegharkraeft.dk\/?p=23353"},"modified":"2025-10-23T19:03:33","modified_gmt":"2025-10-23T18:03:33","slug":"men-multipel-endokrin-neoplasi","status":"publish","type":"post","link":"https:\/\/jegharkraeft.dk\/en\/men-multipel-endokrin-neoplasi\/","title":{"rendered":"Multipel Endokrin Neoplasi. MEN syndrom. MEN1. MEN2. Arvelig kr\u00e6ft endokrin. RET gen. MEN1 gen. F\u00e6okromocytom arvelig. Medull\u00e6r skjoldbruskkirtelkr\u00e6ft. Hyperparathyreoidisme"},"content":{"rendered":"\n<div class=\"wp-block-group alignfull is-style-section-5 has-contrast-color has-base-background-color has-text-color has-background has-link-color wp-elements-53afe16ab24afffca62ef04c27bf7745 has-global-padding is-layout-constrained wp-block-group-is-layout-constrained is-style-section-5--2\" id=\"menu\" style=\"margin-top:0;margin-bottom:0;padding-top:var(--wp--preset--spacing--50);padding-bottom:var(--wp--preset--spacing--50)\">\n<div class=\"wp-block-columns alignwide is-layout-flex wp-container-core-columns-is-layout-ca2dd60b wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\">\n<h2 class=\"wp-block-heading has-custom-int-link-p-sort-1-color has-text-color has-link-color wp-elements-890e3c045e088b3f0eb4325834726146\" id=\"diagnose\"><span class=\"ez-toc-section\" id=\"Diagnose\"><\/span><a href=\"https:\/\/jegharkraeft.dk\/diagnose\" data-type=\"link\" data-id=\"https:\/\/jegharkraeft.dk\/diagnose\">Diagnose<\/a><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<div class=\"wp-block-group has-custom-interne-links-color has-text-color has-link-color wp-elements-c4618f790f619140ad47fc97da79207e has-global-padding is-layout-constrained wp-block-group-is-layout-constrained\">\n<ol class=\"wp-block-list\">\n<li class=\"has-custom-int-link-p-sort-1-color has-text-color has-link-color wp-elements-23b4cb6a772ae26487853362438f6f9e\"><a href=\"https:\/\/jegharkraeft.dk\/hvad-er-kraeft\">Hvad er kr\u00e6ft<\/a><\/li>\n\n\n\n<li class=\"has-custom-int-link-p-sort-1-color has-text-color has-link-color wp-elements-a133d519596fb733a9c4a2e2a27d49bf\"><a href=\"https:\/\/jegharkraeft.dk\/symptomer\">Sy<strong>mptomer<\/strong><\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/jegharkraeft.dk\/kraefttyper\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-custom-hvid-tekst-color\">Kr\u00e6fttyper<\/mark><\/a>\n<ul class=\"wp-block-list\">\n<li class=\"has-custom-int-link-p-sort-1-color has-text-color has-link-color wp-elements-85161ed720c669ff95d38a1e09f286cd\"><a href=\"https:\/\/jegharkraeft.dk\/bugspytkirtelkraeft\">3.A Ford\u00f8jelsesorganer<\/a><\/li>\n\n\n\n<li class=\"has-custom-int-link-p-sort-1-color has-text-color has-link-color wp-elements-f60c1cb33ab94504f06a3d567eac7ef1\"><a href=\"https:\/\/jegharkraeft.dk\/brystkraeft\">3.B K\u00f8nsorganer<\/a><\/li>\n\n\n\n<li class=\"has-custom-int-link-p-sort-1-color has-text-color has-link-color wp-elements-189b11dfa0d506668905cf357de2955e\"><a href=\"https:\/\/jegharkraeft.dk\/hoved-halskraeft\">3.C Hovedet og halsen<\/a><\/li>\n\n\n\n<li class=\"has-custom-int-link-p-sort-1-color has-text-color has-link-color wp-elements-466ad727d686907eeeb5adb4e82a8f02\"><a href=\"https:\/\/jegharkraeft.dk\/leukaemi\">3.D Blod og lymfe<\/a><\/li>\n\n\n\n<li class=\"has-custom-int-link-p-sort-1-color has-text-color has-link-color wp-elements-45e7f5d534f1edcfb30bff2bf7c223a7\"><a href=\"https:\/\/jegharkraeft.dk\/hudkraeft\">3.E Hud<\/a><\/li>\n\n\n\n<li class=\"has-custom-int-link-p-sort-1-color has-text-color has-link-color wp-elements-42d29edcd73d946ea189a1fe871803d7\"><a href=\"https:\/\/jegharkraeft.dk\/blaerekraeft\">3.F Andre organer<\/a><\/li>\n\n\n\n<li class=\"has-custom-int-link-p-sort-1-color has-text-color has-link-color wp-elements-ebc359816354c31432319643069582c2\"><a href=\"https:\/\/jegharkraeft.dk\/alk-mutation\">3.G Genetiske mutationer<\/a><\/li>\n\n\n\n<li class=\"has-custom-int-link-p-sort-1-color has-text-color has-link-color wp-elements-78e4bd2acafb448af2bdb7bef5605441\"><a href=\"https:\/\/jegharkraeft.dk\/parasittens-vej-til-kraeft\">3.H Infektionsrelateret kr\u00e6ft<\/a><a href=\"https:\/\/jegharkraeft.dk\/kraefttyper\"><\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/jegharkraeft.dk\/binyrekraeft\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-custom-hvid-tekst-color\">3.I Endokrine kirtler<\/mark><\/a>\n<ul class=\"wp-block-list\">\n<li class=\"has-custom-int-link-p-sort-1-color has-text-color has-link-color wp-elements-57de8268f67d6e88277cc0241a441b42\"><a href=\"https:\/\/jegharkraeft.dk\/binyrekraeft\">Binyrekr\u00e6ft<\/a><\/li>\n\n\n\n<li class=\"has-custom-int-link-p-sort-1-color has-text-color has-link-color wp-elements-7c77b02f4acb33392e6f382312e6799c\"><a href=\"https:\/\/jegharkraeft.dk\/biskjoldbruskkirtelkraeft\/\">Biskjoldbruskkirtelkr\u00e6ft<\/a><\/li>\n\n\n\n<li class=\"has-custom-int-link-p-sort-1-color has-text-color has-link-color wp-elements-da71ce20195bcf03653bbbfa736c0a51\"><a href=\"https:\/\/jegharkraeft.dk\/hypofyse-kraeft\">Hypofyse kr\u00e6ft<\/a><\/li>\n\n\n\n<li class=\"has-custom-her-st-r-du-color has-text-color has-link-color wp-elements-66cf125b4609e0b6ecda381132c6d189\"><a href=\"#men\">MEN (Multipel Endokrin Neoplasi) (scroll ned)<\/a><\/li>\n\n\n\n<li class=\"has-custom-int-link-p-sort-1-color has-text-color has-link-color wp-elements-eb17278f8ead18ad7028b5b2e770ca92\"><a href=\"https:\/\/jegharkraeft.dk\/neuroendokrine-tumorer\">Neuroendokrine tumorer<\/a><\/li>\n\n\n\n<li class=\"has-custom-int-link-p-sort-1-color has-text-color has-link-color wp-elements-196edbe0ee604ab0aee1b35ce169bfb6\"><a href=\"https:\/\/jegharkraeft.dk\/skjoldbruskkirtelkraeft\">Skjoldbruskkirtelkr\u00e6ft<\/a><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<\/li>\n\n\n\n<li class=\"has-custom-int-link-p-sort-1-color has-text-color has-link-color wp-elements-60a73b2d8f5bf0cd1715ac7d6fc440fc\"><a href=\"https:\/\/jegharkraeft.dk\/kraeftformer\">Kr\u00e6ftformer<\/a><\/li>\n\n\n\n<li class=\"has-custom-int-link-p-sort-1-color has-text-color has-link-color wp-elements-91308c4a8398d249f000f70fe17bcf02\"><a href=\"https:\/\/jegharkraeft.dk\/undersoegelser\">Unders\u00f8gelser<\/a><\/li>\n\n\n\n<li class=\"has-custom-int-link-p-sort-1-color has-text-color has-link-color wp-elements-87af2b6def054da5be4a6efd940116a1\"><a href=\"https:\/\/jegharkraeft.dk\/second-opinion-1\">Second Opinion<\/a><\/li>\n<\/ol>\n<\/div>\n<\/div>\n\n\n\n<div class=\"wp-block-column is-vertically-aligned-center is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:50%\">\n<figure class=\"wp-block-image aligncenter size-full is-resized\"><img loading=\"lazy\" decoding=\"async\" width=\"809\" height=\"809\" src=\"https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2025\/10\/multipel-endokrin-neoplasi11.jpg\" alt=\"Multipel Endokrin Neoplasi symboliseret ved en dna-streng med et lyst punkt i midten. Og bl\u00e5 baggrund.\" class=\"wp-image-23366\" style=\"aspect-ratio:3\/2;object-fit:cover;width:550px\" srcset=\"https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2025\/10\/multipel-endokrin-neoplasi11.jpg 809w, https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2025\/10\/multipel-endokrin-neoplasi11-300x300.jpg 300w, https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2025\/10\/multipel-endokrin-neoplasi11-100x100.jpg 100w, https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2025\/10\/multipel-endokrin-neoplasi11-600x600.jpg 600w, https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2025\/10\/multipel-endokrin-neoplasi11-150x150.jpg 150w, https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2025\/10\/multipel-endokrin-neoplasi11-768x768.jpg 768w\" sizes=\"auto, (max-width: 809px) 100vw, 809px\" \/><\/figure>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n<div class=\"wp-block-group alignfull is-style-default has-global-padding is-layout-constrained wp-container-core-group-is-layout-b040ace0 wp-block-group-is-layout-constrained has-background\" style=\"margin-top:0;margin-bottom:0;padding-top:var(--wp--preset--spacing--60);padding-right:var(--wp--preset--spacing--20);padding-bottom:var(--wp--preset--spacing--60);padding-left:var(--wp--preset--spacing--20);background-image:url(&apos;https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2025\/10\/multipel-endokrin-neoplasi11.jpg&apos;);background-size:cover;\">\n<div class=\"gb-element-906497af\">\n<h1 class=\"wp-block-heading\" id=\"men\"><span class=\"ez-toc-section\" id=\"MEN_Multipel_Endokrin_Neoplasi\"><\/span>MEN (Multipel Endokrin Neoplasi)<span class=\"ez-toc-section-end\"><\/span><\/h1>\n\n\n\n<hr class=\"wp-block-separator has-text-color has-custom-sort-tekst-color has-alpha-channel-opacity has-custom-sort-tekst-background-color has-background\"\/>\n\n\n\n<h4 class=\"wp-block-heading\">Resum\u00e9 om MEN (Multipel Endokrin Neoplasi)<\/h4>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Hvad er MEN:<\/strong> <\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Multipel Endokrin Neoplasi (MEN) er en gruppe sj\u00e6ldne, arvelige syndromer. De skyldes en medf\u00f8dt genfejl, der markant \u00f8ger risikoen for at udvikle tumorer (b\u00e5de godartede og ondartede) i flere af kroppens hormonproducerende (endokrine) kirtler.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>MEN1 vs. MEN2:<\/strong> <\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Man skelner prim\u00e6rt mellem MEN1 (rammer oftest biskjoldbruskkirtler, bugspytkirtel og hypofyse) og MEN2 (rammer oftest skjoldbruskkirtel, binyrer og biskjoldbruskkirtler). MEN2 inddeles yderligere i MEN2A og MEN2B, som har forskellig grad af alvor og symptombillede.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>H\u00e5ndtering og kontrol:<\/strong> <\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Selve genfejlen kan ikke helbredes, men tumorerne kan behandles. H\u00e5ndteringen fokuserer p\u00e5 livslang, regelm\u00e6ssig screening (blodpr\u00f8ver og scanninger) for at opdage og fjerne tumorer s\u00e5 tidligt som muligt, ofte f\u00f8r de giver symptomer.<\/li>\n<\/ul>\n\n\n\n<hr class=\"wp-block-separator has-text-color has-custom-sort-tekst-color has-alpha-channel-opacity has-custom-sort-tekst-background-color has-background\"\/>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Hvad_er_multipel_endokrin_neoplasi_MEN\"><\/span>Hvad er multipel endokrin neoplasi (MEN)<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<figure class=\"wp-block-image size-thumbnail is-resized\"><img loading=\"lazy\" decoding=\"async\" width=\"150\" height=\"150\" src=\"https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2025\/10\/multipel-endokrin-neoplasi12a-150x150.jpg\" alt=\"Multipel Endokrin Neoplasi symboliseret ved principskitse af menneske, hvor der vises de udsatte organer. \" class=\"wp-image-23367\" style=\"width:auto;height:150px\" srcset=\"https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2025\/10\/multipel-endokrin-neoplasi12a-150x150.jpg 150w, https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2025\/10\/multipel-endokrin-neoplasi12a-300x300.jpg 300w, https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2025\/10\/multipel-endokrin-neoplasi12a-100x100.jpg 100w, https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2025\/10\/multipel-endokrin-neoplasi12a-600x597.jpg 600w, https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2025\/10\/multipel-endokrin-neoplasi12a.jpg 650w\" sizes=\"auto, (max-width: 150px) 100vw, 150px\" \/><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">Multipel Endokrin Neoplasi, forkortet MEN, er ikke \u00e9n specifik kr\u00e6ftsygdom. Det er en samlebetegnelse for arvelige syndromer, der skyldes en medf\u00f8dt mutation (fejl) i et specifikt gen. Denne genfejl forstyrrer kroppens normale kontrolmekanismer og medf\u00f8rer en meget h\u00f8j livstidsrisiko for at udvikle tumorer i flere forskellige endokrine kirtler.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">De endokrine kirtler producerer hormoner, der regulerer kroppens funktioner. N\u00e5r tumorer vokser i disse kirtler, kan de enten v\u00e6re godartede (benigne) eller ondartede (maligne\/kr\u00e6ft). Uanset om de er ondartede eller ej, skaber de ofte problemer ved at overproducere hormoner, hvilket kan give en lang r\u00e6kke symptomer.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">At have et MEN-syndrom betyder, at man er i risiko for at udvikle tumorer flere steder og ofte i en yngre alder, end man ellers ville.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Arsager_til_MEN\"><\/span>\u00c5rsager til MEN<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<figure class=\"wp-block-image size-thumbnail is-resized\"><img loading=\"lazy\" decoding=\"async\" width=\"150\" height=\"150\" src=\"https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2025\/10\/multipel-endokrin-neoplasi10-150x150.jpg\" alt=\"Multipel Endokrin Neoplasi symboliseret ved bl\u00e5 baggrund med 3 dna-strenge, der krydser over hinanden. En forgrening i sort i baggrunden.\" class=\"wp-image-23365\" style=\"width:auto;height:150px\" srcset=\"https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2025\/10\/multipel-endokrin-neoplasi10-150x150.jpg 150w, https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2025\/10\/multipel-endokrin-neoplasi10-300x300.jpg 300w, https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2025\/10\/multipel-endokrin-neoplasi10-100x100.jpg 100w, https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2025\/10\/multipel-endokrin-neoplasi10-600x600.jpg 600w, https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2025\/10\/multipel-endokrin-neoplasi10-768x768.jpg 768w, https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2025\/10\/multipel-endokrin-neoplasi10.jpg 1024w\" sizes=\"auto, (max-width: 150px) 100vw, 150px\" \/><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">MEN-syndromer er arvelige og skyldes en mutation i \u00e9t enkelt gen.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>MEN1<\/strong> skyldes en mutation i <em>MEN1<\/em>-genet.<\/li>\n\n\n\n<li><strong>MEN2<\/strong> (b\u00e5de A og B) skyldes en mutation i <a href=\"https:\/\/jegharkraeft.dk\/ret-mutation\/\"><em>RET<\/em>-genet<\/a>.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Syndromerne nedarves &#8220;autosomalt dominant&#8221;. Det betyder, at hvis \u00e9n for\u00e6lder har genfejlen, er der 50 % risiko for, at hvert barn arver den. Det betyder ogs\u00e5, at syndromet rammer m\u00e6nd og kvinder lige hyppigt. Tumorerne kan dog ogs\u00e5 opst\u00e5 som f\u00f8lge af en ny (de novo) mutation, hvor man er den f\u00f8rste i familien, der har den.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"De_forskellige_typer_af_MEN\"><\/span>De forskellige typer af MEN<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<figure class=\"wp-block-image size-thumbnail is-resized\"><img loading=\"lazy\" decoding=\"async\" width=\"150\" height=\"150\" src=\"https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2025\/10\/multipel-endokrin-neoplasi9a-150x150.jpg\" alt=\"Multipel Endokrin Neoplasi symboliseret ved en dna-streng i lysende farve. Fra toppen af denne g\u00e5r 5 strenge i forskellig farve, der illustrerer typer af MEN.\" class=\"wp-image-23369\" style=\"width:auto;height:150px\" srcset=\"https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2025\/10\/multipel-endokrin-neoplasi9a-150x150.jpg 150w, https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2025\/10\/multipel-endokrin-neoplasi9a-300x300.jpg 300w, https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2025\/10\/multipel-endokrin-neoplasi9a-100x100.jpg 100w, https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2025\/10\/multipel-endokrin-neoplasi9a-600x600.jpg 600w, https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2025\/10\/multipel-endokrin-neoplasi9a-768x768.jpg 768w, https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2025\/10\/multipel-endokrin-neoplasi9a.jpg 800w\" sizes=\"auto, (max-width: 150px) 100vw, 150px\" \/><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">Det er afg\u00f8rende at skelne mellem de forskellige typer MEN, da de involverer forskellige kirtler og har forskellig grad af risiko.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\">MEN type 1 (MEN1) <\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">MEN1-syndromet kaldes ogs\u00e5 Wermers syndrom. Det er prim\u00e6rt karakteriseret ved tumorer i tre kirtler (ofte kaldet &#8220;de 3 P&#8217;er&#8221;):<\/p>\n\n\n\n<ol start=\"1\" class=\"wp-block-list\">\n<li><strong>Biskjoldbruskkirtlerne (Parathyroidea):<\/strong> Dette er den mest almindelige (ses hos over 90 %). <br>Tumorerne er n\u00e6sten altid godartede (adenomer), men f\u00f8rer til overproduktion af parathyroideahormon (hyperparathyreoidisme).<\/li>\n\n\n\n<li><strong>Bugspytkirtlen (Pancreas):<\/strong> Her ses neuroendokrine tumorer (NETs), som kan v\u00e6re b\u00e5de godartede og ondartede. <br>De mest almindelige er gastrinomer (giver Zollinger-Ellisons syndrom med maves\u00e5r) og insulinomer (giver lavt blodsukker).<\/li>\n\n\n\n<li><strong>Hypofysen (Pituitary):<\/strong> Tumorer i hypofysen, oftets godartede. <br>Den hyppigste er prolaktinom (producerer for meget prolaktin).<\/li>\n<\/ol>\n\n\n\n<p class=\"wp-block-paragraph\">Personer med MEN1 kan ogs\u00e5 udvikle tumorer i binyrerne (ofte godartede) og godartede tumorer i huden (lipomer).<\/p>\n\n\n\n<h4 class=\"wp-block-heading\">MEN type 2 (MEN2) <\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">MEN2 skyldes mutationer i RET-genet og opdeles i to hovedtyper:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>MEN type 2A (MEN2A)<\/strong> <\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>MEN2A (Sipples syndrom) er den mest almindelige form af MEN2. Den er karakteriseret ved en kombination af:\n<ol class=\"wp-block-list\">\n<li><strong>Medull\u00e6r skjoldbruskkirtelkr\u00e6ft (MTC):<\/strong> Ses hos n\u00e6sten alle (95-100 %). Dette er ofte den f\u00f8rste tumor, der opdages.<\/li>\n\n\n\n<li><strong>F\u00e6okromocytom:<\/strong> En tumor i binyremarven, der producerer stresshormoner (adrenalin\/noradrenalin). Ses hos ca. 50 % og kan forekomme i begge binyrer.<\/li>\n\n\n\n<li><strong>Hyperparathyreoidisme:<\/strong> Tumorer i biskjoldbruskkirtlerne. Ses hos ca. 20-30 % (mindre hyppigt og ofte mildere end ved MEN1).<\/li>\n<\/ol>\n<\/li>\n<\/ul>\n\n\n\n<ol start=\"1\" class=\"wp-block-list\">\n<li><\/li>\n<\/ol>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>MEN type 2B (MEN2B)<\/strong> <\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>MEN2B er mere sj\u00e6lden og generelt mere aggressiv end MEN2A. Den inkluderer:\n<ol class=\"wp-block-list\">\n<li><strong>Medull\u00e6r skjoldbruskkirtelkr\u00e6ft (MTC):<\/strong> Ses hos 100 % og opst\u00e5r ofte meget tidligt i barndommen. Den er typisk mere aggressiv end ved MEN2A.<\/li>\n\n\n\n<li><strong>F\u00e6okromocytom:<\/strong> Ses hos ca. 50 %.<\/li>\n<\/ol>\n<\/li>\n<\/ul>\n\n\n\n<ol start=\"1\" class=\"wp-block-list\">\n<li><\/li>\n<\/ol>\n\n\n\n<p class=\"wp-block-paragraph\">Det, der adskiller MEN2B, er, at man <em>ikke<\/em> udvikler sygdom i biskjoldbruskkirtlerne. <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Til geng\u00e6ld har man andre karakteristiske tr\u00e6k:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Muk\u00f8se neuromer:<\/strong> Sm\u00e5, godartede knuder p\u00e5 tungen, l\u00e6berne og i slimhinderne.<\/li>\n\n\n\n<li>Karakteristisk kropsbygning (marfanoid habitus) med lange, tynde lemmer.<\/li>\n\n\n\n<li>Forstyrrelser i mave-tarm-kanalen.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Symptomer_pa_MEN\"><\/span>Symptomer p\u00e5 MEN<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<figure class=\"wp-block-image size-thumbnail is-resized\"><img loading=\"lazy\" decoding=\"async\" width=\"150\" height=\"150\" src=\"https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2025\/10\/multipel-endokrin-neoplasi8-150x150.jpg\" alt=\"Multipel Endokrin Neoplasi symboliseret ved overkroppen i streg af et menneske. Man kan se skjoldbruskkirtel, tarmkanal, nyre. Bl\u00e5 baggrund.\" class=\"wp-image-23363\" style=\"width:auto;height:150px\" srcset=\"https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2025\/10\/multipel-endokrin-neoplasi8-150x150.jpg 150w, https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2025\/10\/multipel-endokrin-neoplasi8-300x300.jpg 300w, https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2025\/10\/multipel-endokrin-neoplasi8-100x100.jpg 100w, https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2025\/10\/multipel-endokrin-neoplasi8-600x600.jpg 600w, https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2025\/10\/multipel-endokrin-neoplasi8-768x768.jpg 768w, https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2025\/10\/multipel-endokrin-neoplasi8.jpg 1024w\" sizes=\"auto, (max-width: 150px) 100vw, 150px\" \/><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">Symptomerne p\u00e5 MEN kommer ikke fra selve genfejlen, men fra de tumorer, der udvikler sig i de enkelte kirtler. Symptomerne afh\u00e6nger derfor helt af, <em>hvilken<\/em> kirtel der er ramt, og <em>hvilket<\/em> hormon der overproduceres.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Ved hyperparathyreoidisme (MEN1 og MEN2A):<\/strong> <\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Forh\u00f8jet kalk i blodet. Kan give tr\u00e6thed, knoglesmerter, forstoppelse, \u00f8get t\u00f8rst og nyresten.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Ved f\u00e6okromocytom (MEN2A og MEN2B):<\/strong> <\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Anfaldsvise symptomer pga. h\u00f8jt adrenalin. Hjertebanken, hovedpine, svedeture, angst og kraftigt forh\u00f8jet blodtryk.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Ved medull\u00e6r skjoldbruskkirtelkr\u00e6ft (MEN2A og MEN2B):<\/strong> <\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Giver ofte ingen symptomer tidligt. Senere kan m\u00e6rkes en knude p\u00e5 halsen eller h\u00e6vede lymfeknuder.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Ved NET i bugspytkirtlen (MEN1):<\/strong> <\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Symptomer afh\u00e6nger af hormonet. Gastrinomer giver sv\u00e6re maves\u00e5r. Insulinomer giver episoder med meget lavt blodsukker (svimmelhed, forvirring, svedeture).<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Ved hypofysetumorer (MEN1):<\/strong> <\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Prolaktinomer kan give nedsat sexlyst, infertilitet og m\u00e6lkeproduktion (uanset k\u00f8n). Andre tumorer kan give hovedpine eller synsforstyrrelser.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Diagnostik_og_udredning\"><\/span>Diagnostik og udredning<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<figure class=\"wp-block-image size-thumbnail is-resized\"><img loading=\"lazy\" decoding=\"async\" width=\"150\" height=\"150\" src=\"https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2025\/10\/multipel-endokrin-neoplasi7-150x150.jpg\" alt=\"Multipel Endokrin Neoplasi symboliseret ved en mand med kittel, der kigger i et mikroskop. I baggrunden en pc-sk\u00e6rm. I forgrunden en lysende dna-streng. Bl\u00e5 baggrund.\" class=\"wp-image-23362\" style=\"width:auto;height:150px\" srcset=\"https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2025\/10\/multipel-endokrin-neoplasi7-150x150.jpg 150w, https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2025\/10\/multipel-endokrin-neoplasi7-300x300.jpg 300w, https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2025\/10\/multipel-endokrin-neoplasi7-100x100.jpg 100w, https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2025\/10\/multipel-endokrin-neoplasi7-600x600.jpg 600w, https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2025\/10\/multipel-endokrin-neoplasi7-768x768.jpg 768w, https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2025\/10\/multipel-endokrin-neoplasi7.jpg 1024w\" sizes=\"auto, (max-width: 150px) 100vw, 150px\" \/><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">Mistanken om MEN opst\u00e5r typisk i tre situationer:<\/p>\n\n\n\n<ol start=\"1\" class=\"wp-block-list\">\n<li>En person diagnosticeres med en af de typiske tumorer (f.eks. MTC eller f\u00e6okromocytom).<\/li>\n\n\n\n<li>En person har tumorer i mere end \u00e9n af de kirtler, der er associeret med MEN.<\/li>\n\n\n\n<li>Der er en kendt familiehistorie med MEN eller relaterede tumorer.<\/li>\n<\/ol>\n\n\n\n<p class=\"wp-block-paragraph\">Den endelige diagnose stilles ved en gentest (en blodpr\u00f8ve), der analyserer MEN1-genet og RET-genet for mutationer.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Hvis en mutation bliver p\u00e5vist, vil man straks igangs\u00e6tte et screeningsprogram og tilbyde genetisk testning til relevante familiemedlemmer (for\u00e6ldre, s\u00f8skende, b\u00f8rn).<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Behandling_og_kontrol\"><\/span>Behandling og kontrol<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<figure class=\"wp-block-image size-thumbnail is-resized\"><img loading=\"lazy\" decoding=\"async\" width=\"150\" height=\"150\" src=\"https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2025\/10\/multipel-endokrin-neoplasi6-150x150.jpg\" alt=\"Multipel Endokrin Neoplasi symboliseret ved et skjold i gennemsigtigt neon. En modelfigur. Det er placeret i et behandlingsrum.\" class=\"wp-image-23361\" style=\"width:auto;height:150px\" srcset=\"https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2025\/10\/multipel-endokrin-neoplasi6-150x150.jpg 150w, https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2025\/10\/multipel-endokrin-neoplasi6-300x300.jpg 300w, https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2025\/10\/multipel-endokrin-neoplasi6-100x100.jpg 100w, https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2025\/10\/multipel-endokrin-neoplasi6-600x600.jpg 600w, https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2025\/10\/multipel-endokrin-neoplasi6-768x768.jpg 768w, https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2025\/10\/multipel-endokrin-neoplasi6.jpg 1024w\" sizes=\"auto, (max-width: 150px) 100vw, 150px\" \/><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">H\u00e5ndteringen af MEN er en livslang proces, der har to hovedform\u00e5l:<\/p>\n\n\n\n<ol start=\"1\" class=\"wp-block-list\">\n<li>At behandle de tumorer, der allerede er opst\u00e5et.<\/li>\n\n\n\n<li>At screene for og forebygge nye tumorer.<\/li>\n<\/ol>\n\n\n\n<h4 class=\"wp-block-heading\">Behandling af tumorer <\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">Behandlingen er typisk kirurgisk fjernelse af den eller de p\u00e5g\u00e6ldende kirtler\/tumorer.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Hyperparathyreoidisme (MEN1\/MEN2A):<\/strong> Operation, hvor man fjerner de forst\u00f8rrede biskjoldbruskkirtler.<\/li>\n\n\n\n<li><strong>F\u00e6okromocytom (MEN2):<\/strong> Operation for at fjerne binyren. Dette kr\u00e6ver grundig medicinsk forberedelse for at blokere hormonernes effekt og undg\u00e5 farligt h\u00f8jt blodtryk under operationen.<\/li>\n\n\n\n<li><strong>NET i bugspytkirtlen (MEN1):<\/strong> Operation, hvis muligt. Medicin (f.eks. syrepumpeh\u00e6mmere mod gastrinomer) bruges til at kontrollere symptomerne.<\/li>\n\n\n\n<li><strong>Hypofysetumorer (MEN1):<\/strong> Behandles ofte f\u00f8rst med medicin (f.eks. ved prolaktinomer), ellers operation.<\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\">Forebyggende operation (profylakse) <\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">Ved MEN2 (is\u00e6r MEN2B) er risikoen for medull\u00e6r skjoldbruskkirtelkr\u00e6ft 100 %, og den opst\u00e5r ofte tidligt og aggressivt. Derfor anbefaler man st\u00e6rkt en <strong>forebyggende (profylaktisk) fjernelse af hele skjoldbruskkirtlen<\/strong> \u2013 ofte allerede i det f\u00f8rste leve\u00e5r for b\u00f8rn med MEN2B-mutationen, og i den tidlige barndom for MEN2A.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Dette er en omfattende beslutning, men det g\u00f8res for at forhindre en kr\u00e6ftsygdom, der ellers er n\u00e6sten uundg\u00e5elig.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\">Livslang screening <\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">Den vigtigste del af at leve med MEN er det livslange screeningsprogram. Form\u00e5let er at opdage nye tumorer, f\u00f8r de bliver ondartede, eller mens de stadig er meget sm\u00e5 og kan kureres.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Programmet skr\u00e6ddersys til den specifikke MEN-type og genmutation. Det best\u00e5r som standard af:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>\u00c5rlige blod- og urinpr\u00f8ver (m\u00e5ling af kalk, hormoner og tumormark\u00f8rer som calcitonin).<\/li>\n\n\n\n<li>Regelm\u00e6ssige billeddiagnostiske scanninger (MR, CT eller ultralyd) af de relevante organer (hals, brystkasse, mave, hjerne).<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Det kan v\u00e6re en betydelig psykisk belastning at leve med en konstant overv\u00e5gning og bevidstheden om den n\u00e6ste potentielle tumor.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Prognose_og_statistik\"><\/span>Prognose og statistik<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<figure class=\"wp-block-image size-thumbnail is-resized\"><img loading=\"lazy\" decoding=\"async\" width=\"150\" height=\"150\" src=\"https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2025\/10\/multipel-endokrin-neoplasi5-150x150.jpg\" alt=\"Multipel Endokrin Neoplasi symboliseret ved en hospitalsgang med et lysende modelmenneske. Der er en kurve i lys henover dette samt et s\u00f8jlediagram i forgrunden til h\u00f8jre.\" class=\"wp-image-23360\" style=\"width:auto;height:150px\" srcset=\"https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2025\/10\/multipel-endokrin-neoplasi5-150x150.jpg 150w, https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2025\/10\/multipel-endokrin-neoplasi5-300x300.jpg 300w, https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2025\/10\/multipel-endokrin-neoplasi5-100x100.jpg 100w, https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2025\/10\/multipel-endokrin-neoplasi5-600x600.jpg 600w, https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2025\/10\/multipel-endokrin-neoplasi5-768x768.jpg 768w, https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2025\/10\/multipel-endokrin-neoplasi5.jpg 1024w\" sizes=\"auto, (max-width: 150px) 100vw, 150px\" \/><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n\n\n\n<div class=\"wp-block-esab-accordion esab-6lldi71o\" data-mode=\"global\"><div class=\"esab__container\">\n<div class=\"wp-block-esab-accordion-child\"><div class=\"esab__head\" role=\"button\" aria-expanded=\"false\"><div class=\"esab__heading_txt\"><p class=\"esab__heading_tag\">Prognosen for personer med Multipel Endokrin Neoplasi varierer dramatisk og afh\u00e6nger specifikt af:<br>1) Hvilken type (MEN1, MEN2A eller MEN2B) man har<br>2) Om diagnosen stilles proaktivt gennem screening, eller f\u00f8rst efter symptomer er opst\u00e5et.<br><strong>L\u00e6s mere&#8230;<\/strong><\/p><\/div><div class=\"esab__icon\"><div class=\"esab__collapse\"> <svg version=\"1.2\" viewBox=\"0 0 24 24\" width=\"24\" height=\"24\"><path fill-rule=\"evenodd\" d=\"m3.5 20.5c-4.7-4.7-4.7-12.3 0-17 4.7-4.7 12.3-4.7 17 0 4.6 4.7 4.6 12.3 0 17-4.7 4.6-12.3 4.6-17 0zm0.9-0.9c4.2 4.2 11 4.2 15.2 0 4.2-4.2 4.2-11 0-15.2-4.2-4.3-11-4.3-15.2 0-4.3 4.2-4.3 11 0 15.2z\"><\/path><path d=\"m11.4 15.9v-3.3h-3.3c-0.3 0-0.6-0.3-0.6-0.6 0-0.4 0.3-0.6 0.6-0.6h3.3v-3.3c0-0.3 0.3-0.6 0.6-0.6 0.3 0 0.6 0.3 0.6 0.6v3.3h3.3c0.3 0 0.6 0.2 0.6 0.6q0 0.2-0.2 0.4-0.2 0.2-0.4 0.2h-3.3v3.3q0 0.2-0.2 0.4-0.2 0.2-0.4 0.2c-0.4 0-0.6-0.3-0.6-0.6z\"><\/path><\/svg> <\/div><div class=\"esab__expand\"> <svg version=\"1.2\" viewBox=\"0 0 24 24\" width=\"24\" height=\"24\"><path fill-rule=\"evenodd\" d=\"m12 24c-6.6 0-12-5.4-12-12 0-6.6 5.4-12 12-12 6.6 0 12 5.4 12 12 0 6.6-5.4 12-12 12zm10.6-12c0-5.9-4.7-10.6-10.6-10.6-5.9 0-10.6 4.7-10.6 10.6 0 5.9 4.7 10.6 10.6 10.6 5.9 0 10.6-4.7 10.6-10.6z\"><\/path><path d=\"m5.6 11.3h12.8v1.4h-12.8z\"><\/path><\/svg> <\/div><\/div><\/div><div class=\"esab__body\">\n<h4 class=\"wp-block-heading\">MEN1<\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">For MEN1 er den hyppigste tilstand (hyperparathyreoidisme) godartet og p\u00e5virker ikke i sig selv levetiden. Den afg\u00f8rende prognostiske faktor er udviklingen af ondartede tumorer.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Levetid:<\/strong> Flere studier indikerer en statistisk reduceret levetid sammenlignet med baggrundsbefolkningen. \n<ul class=\"wp-block-list\">\n<li>Et hollandsk studie har vist en median-overlevelse p\u00e5 73 \u00e5r, mod 80 \u00e5r i kontrolgruppen.<\/li>\n<\/ul>\n<\/li>\n\n\n\n<li><strong>\u00c5rsager:<\/strong> Den prim\u00e6re \u00e5rsag til nedsat levetid ved MEN1 er ondartede (maligne) neuroendokrine tumorer (NETs), s\u00e6rligt i bugspytkirtlen eller mave-tarm-kanalen, samt carcinoid-tumorer i brislen (thymus).<\/li>\n\n\n\n<li><strong>Risiko:<\/strong> Risikoen for at udvikle en ondartet NET i bugspytkirtlen er betydelig over en livstid. \n<ul class=\"wp-block-list\">\n<li>Prognosen efter en s\u00e5dan diagnose afh\u00e6nger st\u00e6rkt af tumorens stadium og aggressivitet ved opdagelsen.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\">MEN2A <\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">Prognosen for MEN2A er generelt god, men er helt afh\u00e6ngig af h\u00e5ndteringen af medull\u00e6r skjoldbruskkirtelkr\u00e6ft (MTC).<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>MTC-overlevelse:<\/strong> Hvis MTC opdages og behandles tidligt, f.eks. ved forebyggende operation i barndommen, er overlevelsen n\u00e6sten normal. \n<ul class=\"wp-block-list\">\n<li>10-\u00e5rs overlevelsen for MTC, der er begr\u00e6nset til skjoldbruskkirtlen, er over 90-95 %.<\/li>\n<\/ul>\n<\/li>\n\n\n\n<li><strong>Spredning:<\/strong> Hvis MTC derimod har spredt sig (metastaseret) til andre organer, falder 10-\u00e5rs overlevelsen til omkring 40-50 %.<\/li>\n\n\n\n<li><strong>F\u00e6okromocytomer:<\/strong> Disse tumorer i binyrerne er sj\u00e6ldent ondartede (under 5 %), men de er akut farlige, hvis de ikke opdages. \n<ul class=\"wp-block-list\">\n<li>Et udiagnosticeret f\u00e6okromocytom kan udl\u00f8se en livstruende blodtrykskrise under f.eks. anden kirurgi.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\">MEN2B <\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">Dette er historisk set den mest aggressive form af MEN, prim\u00e6rt p\u00e5 grund af MTC, der opst\u00e5r meget tidligt i livet og spreder sig hurtigt.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Historisk prognose:<\/strong> Uden tidlig indgriben var median-levealderen for MEN2B kun omkring 21-25 \u00e5r.<\/li>\n\n\n\n<li><strong>Moderne prognose:<\/strong> Med aggressiv proaktiv behandling \u2013 det vil sige forebyggende fjernelse af skjoldbruskkirtlen inden for det f\u00f8rste leve\u00e5r \u2013 er prognosen forbedret dramatisk.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">For alle MEN-typer g\u00e6lder det, at en t\u00e6t og livslang opf\u00f8lgning i screeningsprogrammet er den enkeltst\u00e5ende vigtigste faktor for at forebygge alvorlig sygdom og bevare en god prognose.<\/p>\n<\/div><\/div>\n<\/div><\/div>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Arvelighed_og_genetisk_vejledning\"><\/span>Arvelighed og genetisk vejledning<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<figure class=\"wp-block-image size-thumbnail is-resized\"><img loading=\"lazy\" decoding=\"async\" width=\"150\" height=\"150\" src=\"https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2025\/10\/multipel-endokrin-neoplasi3-150x150.jpg\" alt=\"Multipel Endokrin Neoplasi symboliseret ved et rum med nogle modelmennesker. Over sidde er en vinkling af to modelstrenge. I baggrunden lysindfald fra et vindue.\" class=\"wp-image-23358\" style=\"width:auto;height:150px\" srcset=\"https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2025\/10\/multipel-endokrin-neoplasi3-150x150.jpg 150w, https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2025\/10\/multipel-endokrin-neoplasi3-300x300.jpg 300w, https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2025\/10\/multipel-endokrin-neoplasi3-100x100.jpg 100w, https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2025\/10\/multipel-endokrin-neoplasi3-600x600.jpg 600w, https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2025\/10\/multipel-endokrin-neoplasi3-768x768.jpg 768w, https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2025\/10\/multipel-endokrin-neoplasi3.jpg 1024w\" sizes=\"auto, (max-width: 150px) 100vw, 150px\" \/><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">Da MEN er arveligt med 50 % risiko for videregivelse, er genetisk vejledning en central del af forl\u00f8bet. Det giver mulighed for at dr\u00f8fte konsekvenserne af at blive testet, herunder betydningen for familieplanl\u00e6gning og forsikringsforhold.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">At f\u00e5 konstateret MEN udl\u00f8ser ofte en kaskade af unders\u00f8gelser hos familiemedlemmer. Det kan v\u00e6re en sv\u00e6r proces at skulle informere sl\u00e6gtninge om, at de ogs\u00e5 kan v\u00e6re i risiko.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Komplementaere_og_alternative_tilgange\"><\/span>Komplement\u00e6re og alternative tilgange<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<figure class=\"wp-block-image size-thumbnail is-resized\"><img loading=\"lazy\" decoding=\"async\" width=\"150\" height=\"150\" src=\"https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2025\/10\/multipel-endokrin-neoplasi2-150x150.jpg\" alt=\"Multipel Endokrin Neoplasi symboliseret ved en skov med en opstilling af sten i zen-formation. Derp\u00e5 balancerer et stykke dna-streng og en plantespire.\" class=\"wp-image-23357\" style=\"width:auto;height:150px\" srcset=\"https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2025\/10\/multipel-endokrin-neoplasi2-150x150.jpg 150w, https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2025\/10\/multipel-endokrin-neoplasi2-300x300.jpg 300w, https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2025\/10\/multipel-endokrin-neoplasi2-100x100.jpg 100w, https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2025\/10\/multipel-endokrin-neoplasi2-600x600.jpg 600w, https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2025\/10\/multipel-endokrin-neoplasi2-768x768.jpg 768w, https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2025\/10\/multipel-endokrin-neoplasi2.jpg 1024w\" sizes=\"auto, (max-width: 150px) 100vw, 150px\" \/><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">Mange s\u00f8ger at supplere den konventionelle behandling med livsstils\u00e6ndringer. Det er vigtigt at fastsl\u00e5, at ingen di\u00e6t, kosttilskud eller alternativ behandling kan \u00e6ndre den underliggende genfejl eller fjerne risikoen for tumorer.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Nogle kan dog opleve, at en struktureret kost kan hj\u00e6lpe med at h\u00e5ndtere symptomer fra hormonel ubalance (f.eks. ved insulinomer eller maves\u00e5r). Ligeledes kan afsp\u00e6ndingsteknikker og mindfulness v\u00e6re v\u00e6rdifulde redskaber til at h\u00e5ndtere den stress og angst, der er forbundet med livslang screening og usikkerheden ved at leve med MEN. En supplerende tilgang b\u00f8r altid dr\u00f8ftes med det behandlende team.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Konklusion\"><\/span>Konklusion<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<figure class=\"wp-block-image size-thumbnail is-resized\"><img loading=\"lazy\" decoding=\"async\" width=\"150\" height=\"150\" src=\"https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2025\/10\/multipel-endokrin-neoplasi1-150x150.jpg\" alt=\"Multipel Endokrin Neoplasi symboliseret ved et lysende menneske, en bred korridor. En lysende pil op. Og nogle runde markeringer med symboler.\" class=\"wp-image-23356\" style=\"width:auto;height:150px\" srcset=\"https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2025\/10\/multipel-endokrin-neoplasi1-150x150.jpg 150w, https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2025\/10\/multipel-endokrin-neoplasi1-300x300.jpg 300w, https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2025\/10\/multipel-endokrin-neoplasi1-100x100.jpg 100w, https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2025\/10\/multipel-endokrin-neoplasi1-600x600.jpg 600w, https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2025\/10\/multipel-endokrin-neoplasi1-768x768.jpg 768w, https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2025\/10\/multipel-endokrin-neoplasi1.jpg 1024w\" sizes=\"auto, (max-width: 150px) 100vw, 150px\" \/><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">At modtage en diagnose med Multipel Endokrin Neoplasi (MEN) er en indgribende livs\u00e6ndring. Tilstanden adskiller sig fundamentalt fra sporadisk opst\u00e5et kr\u00e6ft, da den defineres af en medf\u00f8dt, genetisk disposition, der varer ved hele livet.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Den prim\u00e6re byrde ved MEN er ofte ikke kun de enkelte tumorer, men den psykologiske v\u00e6gt af den konstante overv\u00e5gning. Det er en proces pr\u00e6get af &#8220;vagtsom venten&#8221; og en tilbagevendende usikkerhed ved hver screening, hvilket kan v\u00e6re vanskeligt for omgivelserne at forst\u00e5.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Den viden, gentesten giver, er imidlertid ogs\u00e5 det st\u00e6rkeste forsvar. Den tillader en proaktiv tilgang, hvor man kan v\u00e6re p\u00e5 forkant. For MEN-syndromerne er forskellen p\u00e5 en h\u00e5ndterbar tilstand og en livstruende sygdom n\u00e6sten udelukkende et sp\u00f8rgsm\u00e5l om timing.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Form\u00e5let med h\u00e5ndteringen er ikke at kurere den underliggende genfejl, men at forblive et skridt foran de tumorer, den kan for\u00e5rsage. Gennem specialiseret screening og rettidig indgriben er m\u00e5let at omdanne en genetisk risiko til en kronisk tilstand, der kan h\u00e5ndteres aktivt.<\/p>\n\n\n\n<p class=\"has-custom-menu-links-color has-text-color has-link-color wp-elements-78958270cc4840b7bdca48105c79180e wp-block-paragraph\"><strong><a href=\"#menu\" data-type=\"internal\" data-id=\"#diagnose\">(Til menu)<\/a><\/strong><\/p>\n\n\n\n<h4 class=\"wp-block-heading\">Links<\/h4>\n\n\n\n<p class=\"has-custom-sort-tekst-color has-text-color has-link-color wp-elements-3d017cdd54282aff94247bc9e44d3af5 wp-block-paragraph\">[1] <a href=\"https:\/\/www.sundhed.dk\/borger\/patienthaandbogen\/hormoner-og-stofskifte\/sygdomme\/oevrige-sygdomme\/multiple-endokrine-neoplasier\/\" target=\"_blank\" rel=\"noopener\">Multiple endokrine neoplasier<\/a> (Patienth\u00e5ndbogen p\u00e5 sundhed.dk) <\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Indhold: En central dansk patientinformation, der definerer MEN og beskriver de forskellige typer (MEN1, MEN2A, MEN2B), de involverede kirtler, symptomer og behandlingsprincipper.<\/li>\n<\/ul>\n\n\n\n<p class=\"has-custom-sort-tekst-color has-text-color has-link-color wp-elements-c92a1101e73d10fce88d37f724ea9b87 wp-block-paragraph\">[2] <a href=\"https:\/\/www.rigshospitalet.dk\/undersoegelse-og-behandling\/find-undersoegelse-og-behandling\/sider\/multipel-endokrin-neoplasi-1-men1-29090.aspx\" target=\"_blank\" rel=\"noopener\">Multipel Endokrin Neoplasi 1 <\/a>(MEN1) (Rigshospitalet, ej dateret) <\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Indhold: Specifik information fra Rigshospitalet om MEN1-syndromet, herunder de typiske tumorer i biskjoldbruskkirtler, bugspytkirtel og hypofyse samt det anbefalede kontrolprogram.<\/li>\n<\/ul>\n\n\n\n<p class=\"has-custom-sort-tekst-color has-text-color has-link-color wp-elements-5e7e9349475e9d5337be3cf30f26ddb6 wp-block-paragraph\">[3] <a href=\"https:\/\/www.rigshospitalet.dk\/undersoegelse-og-behandling\/find-undersoegelse-og-behandling\/sider\/multipel-endokrin-neoplasi-2-men2-29089.aspx\" target=\"_blank\" rel=\"noopener\">Multipel Endokrin Neoplasi 2 <\/a>(MEN2) (Rigshospitalet, ej dateret) <\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Indhold: Specifik information fra Rigshospitalet om MEN2, der d\u00e6kker tumorer i skjoldbruskkirtlen (MTC), binyremarven og biskjoldbruskkirtlerne samt det livslange kontrolforl\u00f8b.<\/li>\n<\/ul>\n\n\n\n<p class=\"has-custom-sort-tekst-color has-text-color has-link-color wp-elements-89bdc8965b4302777b82fae04f3781b2 wp-block-paragraph\">[4] <a href=\"https:\/\/www.cancer.dk\/skjoldbruskkirtelkraeft-thyreoideacancer\/fakta\/aarsager\/\" target=\"_blank\" rel=\"noopener\">\u00c5rsager til skjoldbruskkirtelkr\u00e6ft<\/a> (Kr\u00e6ftens Bek\u00e6mpelse, 2025) <\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Indhold: Beskriver den arvelige sammenh\u00e6ng for medull\u00e6r thyreoidea cancer (MTC), specifikt koblingen til MEN2-syndromet og mutationer i <em>RET<\/em>-genet.<\/li>\n<\/ul>\n\n\n\n<p class=\"has-custom-sort-tekst-color has-text-color has-link-color wp-elements-dcce93204387073d13392caf664bdb75 wp-block-paragraph\">[5] <a href=\"https:\/\/my.clevelandclinic.org\/health\/diseases\/23088-multiple-endocrine-neoplasia-men\" target=\"_blank\" rel=\"noopener\">Multiple Endocrine Neoplasia (MEN)<\/a> (Cleveland Clinic, 2022) <\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Indhold: En omfattende international oversigt, der d\u00e6kker diagnostiske kriterier, genetisk testning og symptomer for b\u00e5de MEN1 og MEN2.<\/li>\n<\/ul>\n\n\n\n<p class=\"has-custom-sort-tekst-color has-text-color has-link-color wp-elements-6d7ba8a9e6851a81d8c238b441a0df94 wp-block-paragraph\">[6] <a href=\"https:\/\/medlineplus.gov\/genetics\/condition\/multiple-endocrine-neoplasia\/\" target=\"_blank\" rel=\"noopener\">Multiple endocrine neoplasia<\/a> (MedlinePlus Genetics, NCI, 2017) <\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Indhold: En autoritativ amerikansk kilde, der grundigt gennemg\u00e5r de genetiske \u00e5rsager (MEN1- og RET-generne), arvelighed og de forskellige typer af MEN-syndromet.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">d. 23.10.25<a href=\"https:\/\/jegharkraeft.dk\/second-opinion\"><\/a><\/p>\n\n\n\n<p class=\"has-text-align-center wp-block-paragraph\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-custom-menu-links-color\">\u2764<\/mark><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Hvad du l\u00e6ser p\u00e5 <\/strong><em><strong>Jeg har Kr\u00e6ft<\/strong><\/em><strong> er ikke en anbefaling. S\u00f8g kompetent vejledning.<\/strong><\/p>\n<\/div>\n<\/div>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_83 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Indhold<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><ul class='ez-toc-list-level-2' ><li class='ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/jegharkraeft.dk\/en\/men-multipel-endokrin-neoplasi\/#Diagnose\" >Diagnose<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-1'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/jegharkraeft.dk\/en\/men-multipel-endokrin-neoplasi\/#MEN_Multipel_Endokrin_Neoplasi\" >MEN (Multipel Endokrin Neoplasi)<\/a><ul class='ez-toc-list-level-2' ><li class='ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/jegharkraeft.dk\/en\/men-multipel-endokrin-neoplasi\/#Hvad_er_multipel_endokrin_neoplasi_MEN\" >Hvad er multipel endokrin neoplasi (MEN)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/jegharkraeft.dk\/en\/men-multipel-endokrin-neoplasi\/#Arsager_til_MEN\" >\u00c5rsager til MEN<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/jegharkraeft.dk\/en\/men-multipel-endokrin-neoplasi\/#De_forskellige_typer_af_MEN\" >De forskellige typer af MEN<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/jegharkraeft.dk\/en\/men-multipel-endokrin-neoplasi\/#Symptomer_pa_MEN\" >Symptomer p\u00e5 MEN<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/jegharkraeft.dk\/en\/men-multipel-endokrin-neoplasi\/#Diagnostik_og_udredning\" >Diagnostik og udredning<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/jegharkraeft.dk\/en\/men-multipel-endokrin-neoplasi\/#Behandling_og_kontrol\" >Behandling og kontrol<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/jegharkraeft.dk\/en\/men-multipel-endokrin-neoplasi\/#Prognose_og_statistik\" >Prognose og statistik<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/jegharkraeft.dk\/en\/men-multipel-endokrin-neoplasi\/#Arvelighed_og_genetisk_vejledning\" >Arvelighed og genetisk vejledning<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/jegharkraeft.dk\/en\/men-multipel-endokrin-neoplasi\/#Komplementaere_og_alternative_tilgange\" >Komplement\u00e6re og alternative tilgange<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/jegharkraeft.dk\/en\/men-multipel-endokrin-neoplasi\/#Konklusion\" >Konklusion<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Diagnose MEN (Multipel Endokrin Neoplasi) Resum\u00e9 om MEN (Multipel Endokrin Neoplasi) Hvad er MEN: MEN1 vs. MEN2: H\u00e5ndtering og kontrol: Hvad er multipel endokrin neoplasi (MEN) Multipel Endokrin Neoplasi, forkortet MEN, er ikke \u00e9n specifik kr\u00e6ftsygdom. Det er en samlebetegnelse for arvelige syndromer, der skyldes en medf\u00f8dt mutation (fejl) i et specifikt gen. Denne genfejl [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":23366,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[102,88,91],"tags":[],"class_list":["post-23353","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-endokrine-kirtler","category-diagnose","category-kraefttyper"],"modified_by":"Hanne","wpml_current_locale":"da_DK","wpml_translations":[],"_links":{"self":[{"href":"https:\/\/jegharkraeft.dk\/en\/wp-json\/wp\/v2\/posts\/23353","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jegharkraeft.dk\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jegharkraeft.dk\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jegharkraeft.dk\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/jegharkraeft.dk\/en\/wp-json\/wp\/v2\/comments?post=23353"}],"version-history":[{"count":0,"href":"https:\/\/jegharkraeft.dk\/en\/wp-json\/wp\/v2\/posts\/23353\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/jegharkraeft.dk\/en\/wp-json\/wp\/v2\/media\/23366"}],"wp:attachment":[{"href":"https:\/\/jegharkraeft.dk\/en\/wp-json\/wp\/v2\/media?parent=23353"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jegharkraeft.dk\/en\/wp-json\/wp\/v2\/categories?post=23353"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jegharkraeft.dk\/en\/wp-json\/wp\/v2\/tags?post=23353"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}